Literature DB >> 414952

Single-radial-complement-fixation: a new immunodiffusion technique. 2. Assay of the antibody response to the internal antigens (MP and NP) of influenza A virus in human sera after vaccination and infection.

R Haaheim.   

Abstract

This new immunodiffusion method involves the incorporation of antigen and complement in a primary agarose gel. Heat-inactivated serum samples are filled into wells and allowed to diffuse radially overnight at 4 degrees C. A secondary gel, containing antibody-coated sheep erythrocytes, is layered on top of the first gel and the system is incubated for 45 min at 37 degrees C. Where complement is fixed, i.e. around wells with positive serum samples, zones of unlysed indicator cells appear. Otherwise, the red bloods cells are lysed. This sensitive technique is employed in a study of human sera for the measurement of the antibody response to the internal antigens (MP and NP) of influenza A virus after infection and vaccination. It was found that none of the vaccinees developed antibodies to the MP antigen, whereas 35% of the post-infection group showed a significant rise. The response to the NP antigen was less frequent and of lower order of magnitude after vaccination than after infection.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 414952

Source DB:  PubMed          Journal:  Dev Biol Stand        ISSN: 0301-5149


  8 in total

1.  Single-radial-complement-fixation: a new immunodiffusion technique. Assay of the antibody response to the type-specific antigens of influenza virus in post-infection human sera.

Authors:  L R Haaheim
Journal:  Bull World Health Organ       Date:  1978       Impact factor: 9.408

2.  Single radial complement fixation test for assaying antibody to influenza virus type-specific antigens.

Authors:  N Yamane; M Yuki; Y Nakamura
Journal:  J Clin Microbiol       Date:  1983-10       Impact factor: 5.948

Review 3.  The human antibody response to influenza A virus infection and vaccination.

Authors:  Florian Krammer
Journal:  Nat Rev Immunol       Date:  2019-06       Impact factor: 53.106

4.  Randomized, Double-Blind, Reference-Controlled, Phase 2a Study Evaluating the Immunogenicity and Safety of OVX836, A Nucleoprotein-Based Influenza Vaccine.

Authors:  Isabel Leroux-Roels; Gwenn Waerlop; Jessika Tourneur; Fien De Boever; Catherine Maes; Jacques Bruhwyler; Delphine Guyon-Gellin; Philippe Moris; Judith Del Campo; Paul Willems; Geert Leroux-Roels; Alexandre Le Vert; Florence Nicolas
Journal:  Front Immunol       Date:  2022-04-07       Impact factor: 8.786

5.  Phase 1 Randomized, Placebo-Controlled, Dose-Escalating Study to Evaluate OVX836, a Nucleoprotein-Based Influenza Vaccine: Intramuscular Results.

Authors:  Kanchanamala Withanage; Ilse De Coster; Nathalie Cools; Simonetta Viviani; Jessika Tourneur; Marion Chevandier; Manon Lambiel; Paul Willems; Alexandre Le Vert; Florence Nicolas; Pierre Van Damme
Journal:  J Infect Dis       Date:  2022-08-12       Impact factor: 7.759

6.  Evolutionary features of a prolific subtype of avian influenza A virus in European waterfowl.

Authors:  Michelle Wille; Conny Tolf; Neus Latorre-Margalef; Ron A M Fouchier; Rebecca A Halpin; David E Wentworth; Jayna Ragwani; Oliver G Pybus; Björn Olsen; Jonas Waldenström
Journal:  Virus Evol       Date:  2022-08-27

Review 7.  B Cell Responses against Influenza Viruses: Short-Lived Humoral Immunity against a Life-Long Threat.

Authors:  Jenna J Guthmiller; Henry A Utset; Patrick C Wilson
Journal:  Viruses       Date:  2021-05-22       Impact factor: 5.048

Review 8.  Current Approaches for Diagnosis of Influenza Virus Infections in Humans.

Authors:  Sai Vikram Vemula; Jiangqin Zhao; Jikun Liu; Xue Wang; Santanu Biswas; Indira Hewlett
Journal:  Viruses       Date:  2016-04-12       Impact factor: 5.048

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.